Dapagliflozin
| CAS No. | 461432-26-8 | Cat. No. | BCP01880 |
| Name | Dapagliflozin | ||
| Synonyms | BMS-512148;BMS512148;BMS 512148; | ||
| Formula | C21H25ClO6 | M. Wt | 408.87 |
| Description | Dapagliflozin, also known as BMS-512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin. | ||
| Pathways | Ion Channel/Membrane Transporter GPCR/G Protein | ||
| Targets | SGLT | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.